RAC (Drugs) Practice Test: 2
37 Questions
17 Views

Choose a study mode

Play Quiz
Study Flashcards
Spaced Repetition
Chat to lesson

Podcast

Play an AI-generated podcast conversation about this lesson

Questions and Answers

What is the sponsor's responsibility that was NOT mentioned in the text?

  • Designate appropriately qualified medical person
  • Ensure proper disposal of investigational product (correct)
  • Submitting unanticipated adverse event reports
  • Update the Investigators Brochure as significant
  • How long does the FDA have to file, or refuse to file, an NDA after receipt?

  • 120 days
  • 30 days
  • 45 days
  • 90 days (correct)
  • Which action would NOT be considered obstructing an inspection by the FDA?

  • Failing to schedule an inspection within 30 days (correct)
  • Allowing an investigator to enter but refusing to provide documents
  • A facility not providing an FDA investigator access to records
  • Scheduling an inspection at a date later than requested
  • What is one of the responsibilities that the sponsor must fulfill according to the text?

    <p>Maintaining records of receipt, use and disposition of investigational product</p> Signup and view all the answers

    If a sponsor fails to designate a qualified medical person, what could be the consequence?

    <p>FDA rejection of the NDA application</p> Signup and view all the answers

    What would be a potential outcome if the FDA refuses to accept an NDA?

    <p>Requirement to restart the whole drug development process</p> Signup and view all the answers

    Which scenario would be considered appropriate behavior during an FDA inspection?

    <p>Answering all questions truthfully and allowing access to records</p> Signup and view all the answers

    What should a regulatory professional submit with a Marketing Authorisation Application dossier for a follow-on biologic that is similar to an authorized biologic medicinal product already on the market?

    <p>Full quality dossier</p> Signup and view all the answers

    What should a company do FIRST when receiving a request from a regulatory authority to conduct product testing in compliance with a newly issued regulation?

    <p>Contact the regulatory authority that issued the request</p> Signup and view all the answers

    What is the correct type of Variation to file when developing a follow-on biologic that is similar to an authorized biologic medicinal product?

    <p>File a new Marketing Authorisation Application</p> Signup and view all the answers

    Which of the following correctly describes an Authorized Generic Drug?

    <p>It is a copy of a brand-name drug that is developed independently</p> Signup and view all the answers

    How many days does the reference member state have, after the start of the DCP Assessment Step I, to supply the draft labeling to concerned member states and the applicant?

    <p>14 days</p> Signup and view all the answers

    What aspect of an Authorized Generic Drug distinguishes it from the brand-name drug?

    <p>Not being listed in the Orange Book</p> Signup and view all the answers

    Which type of dossier should be included in the Marketing Authorisation Application for a follow-on biologic?

    <p>Quality dossier containing only comparative data</p> Signup and view all the answers

    Which action would be inappropriate when handling a request from a regulatory authority?

    <p>Ignoring the request and taking no action</p> Signup and view all the answers

    What is the regulatory action required when developing a follow-on biologic that is similar to an authorized biologic medicinal product?

    <p>File a new Marketing Authorisation Application</p> Signup and view all the answers

    What should a company do before initiating product testing related to a regulatory request?

    <p>Verify the validity and authenticity of the request</p> Signup and view all the answers

    If a follow-on biologic is being developed, what type of dossier should be included in the Marketing Authorisation Application?

    <p>Full quality dossier supplemented by comparability data</p> Signup and view all the answers

    Why is it essential for a company to consult with a regulatory authority regarding product testing requirements?

    <p>To ensure alignment with regulations and avoid non-compliance</p> Signup and view all the answers

    What is necessary to demonstrate when submitting a Marketing Authorisation Application for a follow-on biologic?

    <p>Comparability with existing products on the market</p> Signup and view all the answers

    Which scenario best illustrates non-compliance with regulatory product testing requests?

    <p>A company conducts product testing without verifying the authenticity of the request</p> Signup and view all the answers

    What was the primary issue faced by the company?

    <p>The company received a Warning Letter from the FDA regarding their marketed drug product.</p> Signup and view all the answers

    What should be the top priority for the regulatory specialist to minimize legal liability?

    <p>Gather all relevant information for a risk assessment and seek preliminary legal advice.</p> Signup and view all the answers

    How long has the company been marketing the drug in question?

    <p>Over 20 years</p> Signup and view all the answers

    What type of adverse events were reported in relation to the company's drug?

    <p>Minor adverse events</p> Signup and view all the answers

    What was the nature of the legal claim related to the company's product?

    <p>Claim from children whose mothers took a related product during pregnancy</p> Signup and view all the answers

    What should the company's immediate response be regarding the press reports about the legal claim?

    <p>Gather more information before responding</p> Signup and view all the answers

    What is the significance of the Warning Letter from the FDA?

    <p>It indicates a potential regulatory violation that requires immediate action.</p> Signup and view all the answers

    Which term is defined as reported information on a possible causal relationship between an adverse event and a drug, the relationship being unknown or incompletely documented previously?

    <p>Signal</p> Signup and view all the answers

    What is the correct term for a numerical rating that represents the strength of the relationship between an exposure and an outcome?

    <p>Index</p> Signup and view all the answers

    What is a characteristic that can be objectively measured or quantified and represents the presence of disease or abnormality?

    <p>Sign</p> Signup and view all the answers

    Which term refers to subjective evidence of disease or physical disturbance observed by the patient?

    <p>Symptom</p> Signup and view all the answers

    In pharmacovigilance, what term describes unexpected, potentially causal relationships between drugs and adverse events?

    <p>Signal</p> Signup and view all the answers

    Which term represents a measure or characteristic used to monitor or predict outcomes in pharmacovigilance?

    <p>Indicator</p> Signup and view all the answers

    What is the term for a physical finding that is observed by someone other than the patient?

    <p>Sign</p> Signup and view all the answers

    Which term defines a statistical concept used to measure the strength of association between variables?

    <p>Index</p> Signup and view all the answers

    What is the term for an observation that raises concern about a possible drug-adverse event relationship requiring further investigation?

    <p>Indicator</p> Signup and view all the answers

    Study Notes

    Sponsor's Responsibility

    • The sponsor is not responsible for maintaining records of receipt, use, and disposition of investigational product.
    • The sponsor is responsible for designating an appropriately qualified medical person and submitting unanticipated adverse event reports.
    • The sponsor is also responsible for updating the Investigators Brochure as significant new information becomes available.

    NDA Filing

    • The FDA must file or refuse to file an NDA within 60 days after receipt.

    FDA Inspection

    • The FDA considers a facility's failure to produce requested records in a timely manner, without a reasonable explanation, as obstructing an inspection.
    • A facility's refusal to allow an investigator to enter the site or scheduling an inspection at a later date are not considered obstructing an inspection.

    Marketing Authorisation Application

    • A full quality dossier supplemented by the demonstration of comparability is required for a biotechnology company developing a follow-on biologic.

    DCP Assessment

    • The reference member state has 6 days to supply the draft labeling to the concerned member states and applicant after the start of the DCP Assessment Step I.

    Product Testing

    • When receiving a request from a regulatory authority to conduct product testing in compliance with a newly issued regulation, the company should first contact the regulatory authority to discuss the requirement.

    Authorized Generic Drug

    • An authorized generic drug is not listed in the Orange Book.
    • It is a copy of a brand-name drug that is developed and approved by the brand-name manufacturer.
    • It is the same as the brand-name drug in active ingredient, conditions of use, dosage form, strength, route of administration, and (with certain permissible differences) labeling.

    Warning Letter

    • When receiving a Warning Letter from the FDA, the top priority is to gather all pertinent information for a risk-assessment and recommend to the Senior Leadership Team that preliminary legal advice is obtained without delay.

    Adverse Event

    • A signal is reported information on a possible causal relationship between an adverse event and a drug, the relationship being unknown or incompletely documented previously.

    Studying That Suits You

    Use AI to generate personalized quizzes and flashcards to suit your learning preferences.

    Quiz Team

    Related Documents

    RAC (Drugs) Practice Test PDF

    Description

    Test your knowledge of Regulatory Affairs Certification (RAC) related to Drugs with US Based Questions from Pool 01. This practice test covers topics from Domain I and II, including understanding the sponsor’s responsibilities.

    More Like This

    RAC (Drugs) Practice Test: 1
    43 questions

    RAC (Drugs) Practice Test: 1

    PrivilegedMinneapolis avatar
    PrivilegedMinneapolis
    Test 4
    38 questions

    Test 4

    PrivilegedMinneapolis avatar
    PrivilegedMinneapolis
    RAC Chapter 8 - GLP Regulations
    16 questions
    Use Quizgecko on...
    Browser
    Browser